COMPASS Pathways reports Q1 2022 net loss of $21.2M; cash $243.7M; FDA end-of-phase II meeting held

COMPASS Pathways plc

2022-Q1 EPS reported -$0.50

Net loss $21.2M ($0.50/sh) vs $12.7M ($0.35) in Q1 2021; R&D expenses $15.4M (up from $6.9M).
Cash and cash equivalents $243.7M as of March 31, 2022, down from $273.2M at Dec 31, 2021.
End-of-phase II meeting with FDA completed; finalizing Phase III design for TRD program targeting H2 2022.
Awarded Innovation Passport under UK MHRA ILAP for COMP360 psilocybin therapy.
Phase II trial in PTSD ongoing; collaboration with King's College London and NHS for mental health research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.